The efficacy of teclistamab, a bispecific antibody targeting B-cell maturation antigen and CD3, as early-line monotherapy in relapsed or refractory multiple myeloma is unclear. We randomly assigned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results